The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12625001029482p
Ethics application status
Submitted, not yet approved
Date submitted
20/08/2025
Date registered
17/09/2025
Date last updated
17/09/2025
Date data sharing statement initially provided
17/09/2025
Type of registration
Prospectively registered

Titles & IDs
Public title
Early pain intervention after total knee replacement (EPIK): A registry-nested randomised controlled trial (RCT)
Scientific title
Early pain intervention after total knee replacement (EPIK): A registry-nested randomised controlled trial (RCT)
Secondary ID [1] 315114 0
None
Universal Trial Number (UTN)
Trial acronym
EPIK
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Knee osteoarthritis 338529 0
Total knee replacement 338869 0
Condition category
Condition code
Musculoskeletal 334835 334835 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Intervention group – EPIK model of care (in addition to usual care):
Within 2 weeks of randomisation, participants receive an initial ~1-hour telehealth assessment by a trial clinician trained in study procedures. The assessment reviews medical history, surgical information and patient-reported outcome measures, alongside additional questionnaires to identify prognostic factors for poor outcomes. Based on findings, the clinician develops a personalised care plan that refers participants to existing services based on their needs (e.g. orthopaedic surgeon, GP, physiotherapy, psychological services).

Participants are then followed up by the same clinician via telephone up to six times over 12 months (at ~2, 3, 4, 8, 9 and 10 months after the initial assessment). Follow-up calls last approximately 15–30 minutes and address progress, barriers, and further referrals if required.

Training: Trial clinicians will be trained using a manual that will be developed from extensive qualitative and co-design research. The manual’s authors will deliver training before trial commencement, and all clinicians will also complete Online Pain Education Network (OPEN) e-learning modules.

Adherence: Adherence will be assessed by the proportion of follow-up calls completed and the proportion of recommended services attended.
Intervention code [1] 331738 0
Rehabilitation
Intervention code [2] 331740 0
Treatment: Other
Comparator / control treatment
Usual care: Follow-up and treatment consistent with local processes and surgeon preference following primary total knee replacement for osteoarthritis. This typically includes review by the surgeon and/or general practitioner and a standard rehabilitation program provided by local services at 6–12 weeks post-operatively. There are no specific restrictions placed on care-seeking in this group.
Control group
Active

Outcomes
Primary outcome [1] 342467 0
The Oxford Knee Score (OKS) is a validated patient-reported outcome measure that provides a composite score of both pain and function following total knee replacement. Accordingly, pain and function are assessed together as a composite primary outcome measure in this trial.
Timepoint [1] 342467 0
12 months post-randomisation (primary timepoint)
Secondary outcome [1] 450932 0
Knee-specific pain and function
Timepoint [1] 450932 0
6 months post-randomisation
Secondary outcome [2] 450933 0
Self-reported surgical complications
Timepoint [2] 450933 0
6 months post-randomisation
Secondary outcome [3] 450934 0
Pain intensity and pain interference will be assessed together as a validated composite outcome measure
Timepoint [3] 450934 0
6 and 12 months post-randomisation
Secondary outcome [4] 450935 0
Health-related quality of life
Timepoint [4] 450935 0
6 and 12 months post-randomisation
Secondary outcome [5] 450936 0
Satisfaction with surgical outcome and overall care post TKR will be assessed as a single composite secondary outcome
Timepoint [5] 450936 0
6 and 12 months post-randomisation
Secondary outcome [6] 450937 0
Reoperation for any reason Any additional surgical procedures related to the initial TKR
Timepoint [6] 450937 0
6 and 12 months post-randomisation
Secondary outcome [7] 450938 0
Revision joint replacement
Timepoint [7] 450938 0
6 and 12 months post-randomisation
Secondary outcome [8] 450939 0
Hospital readmission (all cause)
Timepoint [8] 450939 0
6 and 12 months post-randomisation
Secondary outcome [9] 450941 0
Anxiety and depression
Timepoint [9] 450941 0
6 and 12 months post-randomisation
Secondary outcome [10] 450942 0
Pain catastrophising
Timepoint [10] 450942 0
6 and 12 months post-randomisation
Secondary outcome [11] 450943 0
Mortality
Timepoint [11] 450943 0
6 and 12 months post-randomisation
Secondary outcome [12] 451696 0
Health resource utilisation
Timepoint [12] 451696 0
12 months post-randomisation
Secondary outcome [13] 451697 0
Cost-effectiveness
Timepoint [13] 451697 0
12 months post-randomisation.

Eligibility
Key inclusion criteria
Patients (aged greater than or equal to 18 years) undergoing primary total knee replacement for the diagnosis of osteoarthritis.
OKS pain subscale score of 14 or lower at 3 months after their TKR
Patients able to provide verbal and written consent in English
Minimum age
18 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Patients booked for a revision knee procedure at the time of consent
Lack of capacity to provide informed consent
Participation in another study that would interfere with the trial

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
An independent statistician not involved in any aspect of the study will generate the randomisation sequence, thus ensuring allocation is concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomised into either the EPIK model of care or usual care alone at a 1:1 ratio using using minimisation based on the following factors: type of hospital (public vs. private), level of pain (OKS pain component score less than or equal to 7 vs. greater than 7), age (less than or equal to 65 vs. greater than 65 years), sex (male vs. female) and presence of complications requiring treatment after TKR (yes vs. no). Randomisation will be at the patient-level since there is minimal risk of contamination at 3 months post-operatively with the participant based in the community. The randomisation will be performed via an interactive web response service.
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 319691 0
Government body
Name [1] 319691 0
National Health and Medical Research Council (NHMRC)
Country [1] 319691 0
Australia
Funding source category [2] 319694 0
Charities/Societies/Foundations
Name [2] 319694 0
Ramsay Hospital Research Foundation
Country [2] 319694 0
Australia
Primary sponsor type
University
Name
The University of New South Wales
Address
Country
Australia
Secondary sponsor category [1] 322198 0
None
Name [1] 322198 0
NONE
Address [1] 322198 0
Country [1] 322198 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 318250 0
Sydney Local Health District Ethics Review Committee (RPAH Zone)
Ethics committee address [1] 318250 0
Ethics committee country [1] 318250 0
Australia
Date submitted for ethics approval [1] 318250 0
08/09/2025
Approval date [1] 318250 0
Ethics approval number [1] 318250 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 143574 0
Prof Sam Adie
Address 143574 0
UNSW SYDNEY, Suite 201, Level 2, 131 Princes Highway Cnr South St, Kogarah NSW 2217
Country 143574 0
Australia
Phone 143574 0
+61 2 9587 4720
Fax 143574 0
Email 143574 0
Contact person for public queries
Name 143575 0
Khuong Duy Hoang
Address 143575 0
Khuong Duy Hoang, Level 26, 201 Kent St, Sydney NSW 2000, Australia
Country 143575 0
Australia
Phone 143575 0
+61 8 8128 4405
Fax 143575 0
Email 143575 0
Contact person for scientific queries
Name 143576 0
Sam Adie
Address 143576 0
UNSW Sydney, Suite 201, Level 2, 131 Princes Highway Cnr South St, Kogarah NSW 2217
Country 143576 0
Australia
Phone 143576 0
+61 2 9587 4720
Fax 143576 0
Email 143576 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.